Roche Holding is a holding company in the pharmaceutical industry. It is one of the leading manufacturers of biotech pharmaceuticals in the fields of oncology, virology, rheumatology and transplantology. The group includes the Swiss pharmaceutical company - F. Hoffmann-La Roche, Japanese Chugai, American Genentech and Foundation Medicine.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Roche Holding news
30.03.2022
Roche's new immunotherapy Skyscraper 2 has failed to slow the progression of lung cancer. Roche will continue testing another drug against various types of cancer, tiragolumab.
Source: 
reuters.com
reuters.com
03.02.2022
Roche Holding's IFRS net income for 9 months of fiscal year 2021 was CHF14.935 billion, down 0.9% from CHF15.068 billion in the previous year. Revenues rose 7.7% to CHF62.801 billion versus CHF58.323 billion a year earlier.
Source: 
roche.com
roche.com
31.01.2022
FDA has approved Roche's Vabysmo, a drug for the treatment of vision loss. Vabysmo is designed to treat neovascular NVMD and DME by neutralizing angiopoietin-2. A course of treatment for nVMD and DMO is given four times a month. The drug will go on sale in the U.S. in the coming weeks. The European Medicines Agency is also considering an application to regis...
Source: roche.com
roche.com
27.12.2021
The Swiss regulator approved Ronapreve developed by Roche and Regeneron. The antibody-based drug is indicated for the treatment of COVID-19. At the time of the decision, no data were available on the efficacy of Ronapreve against the Omicron strain.
Source: reuters.com
reuters.com
General information
| Company name | Roche Holding |
|---|---|
| Tags | #katie wood's choice, #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | Grenzacherstrasse 124 Basel 4058 Switzerland |
| Mailing address | Grenzacherstrasse 124 Basel 4058 Switzerland |
| Website | www.roche.com |
English (US) 